Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
EXEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.14 - $40.02
Previous CloseN/A
Volume463.09K
Average Volume (3M)2.65M
Market Cap
$10.05B
Enterprise Value$9.08B
Total Cash (Recent Filing)$95.34M
Total Debt (Recent Filing)$234.91M
Price to Earnings (P/E)20.6
Beta0.32
Next Earnings
May 13, 2025EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.77
Shares Outstanding275,583,950
10 Day Avg. Volume2,498,156
30 Day Avg. Volume2,649,058
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)N/A
Price to Sales (P/S)4.77
Price to Cash Flow (P/CF)10.80
P/FCF Ratio10.80
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.19
Enterprise Value/Ebitda12.63
Forecast
1Y Price Target
$37.93Price Target Upside3.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Exelixis News
PremiumCompany Announcements
Exelixis Launches Special Equity Award Program
---
Bulls Say, Bears Say
Bulls Say
Approval And Market LaunchThe approval of cabozantinib came ahead of the expected schedule, which indicates strong execution and potential for a fast market launch.
Financial PerformanceExelixis recorded diluted net income that exceeded previous forecasts, indicating stronger-than-expected profitability.
Market Growth PotentialThere is a significant growth opportunity for Exelixis in the NET market, with management expecting a peak of $3B, highlighting the strong potential for expansion.
Bears Say
Commercial ChallengesRisks include commercial challenges with Cabometyx, potential failure to generate favorable clinical data, and possible generic erosion.
Market UncertaintyThere is a lack of clarity surrounding the size of the market opportunity in neuroendocrine tumors, which has generated debate even though there is significant unmet need in the space.
Safety ConcernsIn the pNET cohort 46% of patients receiving cabo had a serious adverse event, with 49% dose reduction and 19% permanently discontinued cabo due to an adverse event.
---
Ownership Overview
3.75% Insiders
24.82% Mutual Funds
0.38% Other Institutional Investors
42.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $20.14 and its highest was $40.02 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $10.05B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is May 13, 2025 which is in 19 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Feb 11, 2025. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.425 by $0.055.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.36.
How many shares outstanding does Exelixis have?
Exelixis has 275,583,950 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.48 in its last earnings report, beating expectations of $0.425. Following the earnings report the stock price went down -0.03%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
---
Exelixis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.93 (3.13% Upside)
$37.93 (3.13% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.92%
12-Months-Change
Fundamentals
Return on Equity
23.13%
Trailing 12-Months
Asset Growth
-0.31%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of new therapies for the treatment of cancer. The company is headquartered in Alameda, California, and operates primarily within the pharmaceutical and biotechnology sectors. Exelixis is best known for its flagship product, CABOMETYX (cabozantinib), which is used to treat various forms of cancer, including renal cell carcinoma and hepatocellular carcinoma. The company also engages in the development of other small molecule therapies aimed at improving cancer treatment outcomes.
---
EXEL Company Deck
---
EXEL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Exelixis with strong growth in its cabozantinib franchise, significant regulatory and pipeline advancements, and a robust financial position. While there are challenges with increased operating expenses and gross to net deductions, the overall trajectory indicates momentum and growth opportunities.Read More>---
EXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
---
EXEL Stock 12 Month Forecast
Average Price Target
$37.93
▲(3.13% Upside)
Technical Analysis
Best Analysts Covering EXEL
1 Year
1 Year Success Rate
19/22 ratings generated profit
1 Year Average Return
+22.65%
reiterated a buy rating 2 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 86.36% of your transactions generating a profit, with an average return of +22.65% per trade.
---